Article Sidebar
Views pdf: 147
TREATMENT OUTCOME OF USING GEMCITABINE – CISPLATIN FOR RECURRENT AND METASTATIC NASOPHYLARYNGOLOGY CANCER
Main Article Content
Abstract
Objective: To evaluate the treatment outcome and adverse events of Gemcitabine - Cisplatin for recurrent and metastatic nasopharyngeal cancer (NPC) patients at Hanoi Oncology Hospital. Subject and methods: This retrospective combined prospective study was conducted on patients with recurrent and metastatic NPC at Hanoi Oncology Hospital from March 2023 to October 2023. Results: 31 patients were eligible in the study. The overall response rate in the study was 76.9%, of which 11.5% of patients achieved complete response, 65.4% achieved partial response, 19.3% had stable disease, and 3.8% had progressive disease. The adverse events of the regimen were 83.9%, but were mainly grade 1 and 2. Common adverse events were on the hematopoietic, digestive, and nervous systems. Conclusion: Gemcitabine - Cisplatin is a regimen with a high response rate and is safe in the treatment of recurrent and metastatic nasopharyngeal carcinoma.
Article Details
Keywords
Nasopharyngeal cancer, recurrent, metastatic, Gemcitabine – Cisplatin
References
2. Sun XS, L.Y., et al, Establishment and validation of a nomogram for predicting survival in patients with de novo metastatic nasopharyngeal carcinoma. Oral Oncol, 2019. 94: p. 73-79.
3. Chen YP, C.A., et al, Nasopharyngeal carcinoma. Lancet, 2019. 394(10192): p. 64-80.
4. Jin Y, S.Y., et al, Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol, 2012. 138(10): p. 1717-25.
5. Hong S, Z.Y., et al, Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. J Clin Oncol, 2021. 39(29): p. 3273-3282.
6. Yang Q, N.Y., et al, Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma. Drug Des Devel Ther, 2022(16): p. 1191-1198.
7. Ngan RK, Y.H., et al, Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol, 2002. 13(8): p. 1252-8.
8. Li Zhang, Y.H., et al, Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Recurrent or Metastatic Nasopharyngeal Carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet, 2016. 6736(16): p. 31388-5.
9. Raja, J.M.G.A., Cisplatin. National Center for Biotechnology Information, 2023.